ANTIBE THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.295 CAD | 0.00% |
|
0.00% | -68.28% |
| Apr. 24 | Antibe Therapeutics Inc. Announces Board Resignations | CI |
| Apr. 19 | Antibe Therapeutics Seeks Extension of Stay of Proceedings | MT |
Valuation
| Fiscal Period: März | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 69.37 | 178.8 | 232.2 | 41.14 | 31.56 | 15.64 | - | - |
| Enterprise Value (EV) 1 | 69.37 | 178.8 | 160.5 | 41.14 | 31.56 | 15.64 | 15.64 | 15.64 |
| P/E ratio | -4.75 x | -8.71 x | -7.27 x | -1.58 x | -1.62 x | -0.8 x | -1.02 x | -0.66 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 7.27 x | 17.9 x | 23.9 x | 3.04 x | - | - | - | - |
| EV / Revenue | 7.27 x | 17.9 x | 23.9 x | 3.04 x | - | - | - | - |
| EV / EBITDA | -5.89 x | -13.1 x | -9.76 x | -2.07 x | -1.78 x | -0.7 x | - | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 24,339 | 29,310 | 45,626 | 52,076 | 52,594 | 53,009 | - | - |
| Reference price 2 | 2.850 | 6.100 | 5.090 | 0.7900 | 0.6000 | 0.2950 | 0.2950 | 0.2950 |
| Announcement Date | 7/16/19 | 7/24/20 | 6/28/21 | 6/29/22 | 6/29/23 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: März | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 9.539 | 9.987 | 9.7 | 13.51 | - | - | - | - |
| EBITDA 1 | -11.77 | -13.69 | -23.78 | -19.91 | -17.74 | -22.3 | - | - |
| EBIT 1 | -12.19 | -17.63 | -24.26 | -25.53 | -20.55 | -20.83 | -15.27 | -23.76 |
| Operating Margin | -127.77% | -176.57% | -250.12% | -188.95% | - | - | - | - |
| Earnings before Tax (EBT) 1 | -12.68 | -19.35 | -24.73 | -25.25 | -19.29 | -19.51 | -15.27 | -23.76 |
| Net income 1 | -12.82 | -19.34 | -26.3 | -25.06 | -19.48 | -19.51 | -15.27 | -23.76 |
| Net margin | -134.36% | -193.67% | -271.13% | -185.48% | - | - | - | - |
| EPS 2 | -0.6000 | -0.7000 | -0.7000 | -0.5000 | -0.3700 | -0.3700 | -0.2900 | -0.4500 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 7/16/19 | 7/24/20 | 6/28/21 | 6/29/22 | 6/29/23 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.755 | - | 3.965 | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | -5.745 | -3.761 | -4.705 | -5.053 | -5.7 | -3.853 | -3.131 | -5.864 | -5.529 | -4.154 | - | - | - | - | - |
| EBIT 1 | -8.389 | -5.234 | -5.454 | -5.796 | -6.506 | -4.662 | -3.582 | -6.28 | -5.449 | -4.596 | -4.508 | -4.18 | -3.899 | -3.685 | -3.504 |
| Operating Margin | -304.5% | - | -137.55% | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -8.675 | -5.219 | -5.286 | -5.601 | -6.248 | -4.205 | -3.236 | -5.786 | -5.006 | -4.213 | -4.508 | -4.18 | -3.899 | -3.685 | -3.504 |
| Net income 1 | -8.675 | -4.849 | -5.239 | -5.5 | -6.079 | -4.316 | -3.548 | -5.786 | -5.006 | -4.213 | -4.508 | -4.18 | -3.899 | -3.685 | -3.504 |
| Net margin | -314.88% | - | -132.13% | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.1700 | -0.0900 | -0.1100 | -0.1000 | -0.1200 | -0.0800 | -0.0700 | -0.1100 | -0.1000 | -0.0800 | -0.0900 | -0.0800 | -0.0700 | -0.0700 | -0.0700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 2/14/22 | 6/29/22 | 8/15/22 | 11/14/22 | 2/14/23 | 6/29/23 | 8/14/23 | 11/13/23 | 2/14/24 | - | - | - | - | - |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | 71.7 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 7/16/19 | 7/24/20 | 6/28/21 | 6/29/22 | 6/29/23 | - | - | - |
1CAD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.295
CAD
Average target price
2
CAD
Spread / Average Target
+577.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -68.28% | 11.42M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ATE Stock
- Financials Antibe Therapeutics Inc.
